Latest

Every verified treatment and trial we have published, newest first. Filter by country, access level, or patient stories.

All countries United States Canada United Kingdom Japan China Australia Switzerland European Union Newest Patient Stories EMA Authorised ×

EMA AuthorisedEuropean Union

First EU Medicine for Early Brain ALD in Boys Ages 2–12

Nezglyal (leriglitazone) — oral suspension for early cerebral adrenoleukodystrophy (Gd-negative)

The European Commission authorised Nezglyal (leriglitazone) on 21 September 2026, under exceptional circumstances.

This is for boys aged 2 to 12 with early cerebral adrenoleukodystrophy (cALD) — Gd-negative brain lesions on MRI and a Neurological Functional Score of 0 or 1…

September 25, 2026